Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: ACTH, Placebo; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Relapsing Multiple Sclerosis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Monomethyl Fumarate; Drug
Lead sponsor: Banner Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 5 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Diet; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Methotrexate, IV methylprednisolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Ofatumumab, Disease modifying treatment (DMT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more

Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions: BIIB019 (Daclizumab); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 1,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 85
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B; Other
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo; Drug
Lead sponsor: Synthon BV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more

Conditions: Multiple Sclerosis, Relapsing-remitting
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Simnad, Virginia, M.D.; Individual
Eligibility: 21 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Multiple Sclerosis
Interventions: Cladribine, Placebo, Interferon-beta (IFN-beta); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 21
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more

Conditions: Multiple Sclerosis
Interventions: Acthar Gel; Drug
Lead sponsor: Tanner Foundation for Multiple Sclerosis; Other
Eligibility: 19 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Ocrelizumab, Ofatumumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Lutherville, Maryland

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017 (peginterferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 12
States / cities: Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 31
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more

Conditions: Multiple Sclerosis
Interventions: Placebo, Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 35 more

Conditions: Multiple Sclerosis
Interventions: ONO-4641, ONO-4641 placebo; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 19 more

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 8
States / cities: Los Angeles, California • Walnut Creek, California • Shreveport, Louisiana + 5 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Tysabri; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: West Orange, New Jersey

Search by objective public record fields.

ACTH for Fatigue in Multiple Sclerosis Patients

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis

AVONEX® Combination Trial - "ACT"

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Adherence Trial With MS LifeLines ® Services

Efficacy and Safety of GTR in Comparison to Copaxone®

Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

Comprehensive Analysis of Relapse in Multiple Sclerosis

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

Examining Effects of Tysabri on Cognitive Fatigue Using fMRI